APO Research
Talk to an analyst

APO RESEARCH · REPORT

Manufacturing Execution Systems for Pharma and Biotech

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Manufacturing Execution Systems for Pharma and Biotech Market Analysis and Forecast 2026-2032

1 January 2026207 pages

Choose your research edition.

Industry ResearchManufacturing Execution Systems for Pharma and Biotech Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Manufacturing Execution Systems for Pharma and Biotech Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Manufacturing Execution Systems for Pharma and Biotech Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Manufacturing Execution Systems for Pharma and Biotech Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Manufacturing Execution Systems for Pharma and Biotech Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Manufacturing Execution Systems for Pharma and Biotech market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Manufacturing Execution Systems for Pharma and Biotech is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Manufacturing Execution Systems for Pharma and Biotech is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Manufacturing Execution Systems for Pharma and Biotech is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Manufacturing Execution Systems for Pharma and Biotech is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Manufacturing Execution Systems for Pharma and Biotech include Lonza, Vimachem, Korber, MasterControl, POMS Corporation, AspenTech, GE Vernova, 凯睿德 and Dassault Systemes, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Manufacturing Execution Systems for Pharma and Biotech, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Manufacturing Execution Systems for Pharma and Biotech, also provides the revenue of main regions and countries. Of the upcoming market potential for Manufacturing Execution Systems for Pharma and Biotech, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Manufacturing Execution Systems for Pharma and Biotech revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Manufacturing Execution Systems for Pharma and Biotech market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Manufacturing Execution Systems for Pharma and Biotech revenue, projected growth trends, production technology, application and end-user industry.

Manufacturing Execution Systems for Pharma and Biotech Segment by Company

Lonza

Vimachem

Korber

MasterControl

POMS Corporation

AspenTech

GE Vernova

凯睿德

Dassault Systemes

IBM

Rockwell Automation

ABB

Accevo Systems

AmpleLogic

Siemens Software

NNIT

Metronik

Tulip

Manufacturing Execution Systems for Pharma and Biotech Segment by Type

Cloud-based

On-premises

Manufacturing Execution Systems for Pharma and Biotech Segment by Application

Large Enterprises

SMEs

Manufacturing Execution Systems for Pharma and Biotech Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Manufacturing Execution Systems for Pharma and Biotech market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Manufacturing Execution Systems for Pharma and Biotech and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Manufacturing Execution Systems for Pharma and Biotech.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Manufacturing Execution Systems for Pharma and Biotech in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Manufacturing Execution Systems for Pharma and Biotech company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Manufacturing Execution Systems for Pharma and Biotech revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Manufacturing Execution Systems for Pharma and Biotech Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Cloud-based Major Player Table 3. On-premises Major Player Table 4. Global Manufacturing Execution Systems for Pharma and Biotech Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Large Enterprises Major Player Table 6. SMEs Major Player Table 7. Manufacturing Execution Systems for Pharma and Biotech Industry Trends Table 8. Manufacturing Execution Systems for Pharma and Biotech Industry Drivers Table 9. Manufacturing Execution Systems for Pharma and Biotech Industry Opportunities and Challenges Table 10. Manufacturing Execution Systems for Pharma and Biotech Industry Restraints Table 11. Global Manufacturing Execution Systems for Pharma and Biotech Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Manufacturing Execution Systems for Pharma and Biotech Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Manufacturing Execution Systems for Pharma and Biotech Market Share by Region (2021-2026) Table 14. Global Manufacturing Execution Systems for Pharma and Biotech Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Manufacturing Execution Systems for Pharma and Biotech Market Share by Region (2027-2032) Table 16. Global Manufacturing Execution Systems for Pharma and Biotech Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Manufacturing Execution Systems for Pharma and Biotech Revenue Market Share by Players (2021-2026) Table 18. Global Manufacturing Execution Systems for Pharma and Biotech Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Manufacturing Execution Systems for Pharma and Biotech Key Players Headquarters & Area Served Table 20. Global Manufacturing Execution Systems for Pharma and Biotech Players, Product Type & Application Table 21. Global Manufacturing Execution Systems for Pharma and Biotech Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Manufacturing Execution Systems for Pharma and Biotech by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Manufacturing Execution Systems for Pharma and Biotech Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Manufacturing Execution Systems for Pharma and Biotech Revenue Market Share by Type (2021-2026) Table 28. Global Manufacturing Execution Systems for Pharma and Biotech Revenue Market Share by Type (2027-2032) Table 29. Global Manufacturing Execution Systems for Pharma and Biotech Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Manufacturing Execution Systems for Pharma and Biotech Revenue Market Share by Application (2021-2026) Table 33. Global Manufacturing Execution Systems for Pharma and Biotech Revenue Market Share by Application (2027-2032) Table 34. Lonza Company Information Table 35. Lonza Business Overview Table 36. Lonza Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Lonza Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 38. Lonza Recent Development Table 39. Vimachem Company Information Table 40. Vimachem Business Overview Table 41. Vimachem Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Vimachem Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 43. Vimachem Recent Development Table 44. Korber Company Information Table 45. Korber Business Overview Table 46. Korber Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Korber Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 48. Korber Recent Development Table 49. MasterControl Company Information Table 50. MasterControl Business Overview Table 51. MasterControl Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. MasterControl Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 53. MasterControl Recent Development Table 54. POMS Corporation Company Information Table 55. POMS Corporation Business Overview Table 56. POMS Corporation Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. POMS Corporation Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 58. POMS Corporation Recent Development Table 59. AspenTech Company Information Table 60. AspenTech Business Overview Table 61. AspenTech Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. AspenTech Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 63. AspenTech Recent Development Table 64. GE Vernova Company Information Table 65. GE Vernova Business Overview Table 66. GE Vernova Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. GE Vernova Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 68. GE Vernova Recent Development Table 69. 凯睿德 Company Information Table 70. 凯睿德 Business Overview Table 71. 凯睿德 Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. 凯睿德 Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 73. 凯睿德 Recent Development Table 74. Dassault Systemes Company Information Table 75. Dassault Systemes Business Overview Table 76. Dassault Systemes Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Dassault Systemes Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 78. Dassault Systemes Recent Development Table 79. IBM Company Information Table 80. IBM Business Overview Table 81. IBM Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. IBM Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 83. IBM Recent Development Table 84. Rockwell Automation Company Information Table 85. Rockwell Automation Business Overview Table 86. Rockwell Automation Manufacturing Execution Systems for Pharma and Biotech Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Rockwell Automation Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 88. Rockwell Automation Recent Development Table 89. ABB Company Information Table 90. ABB Business Overview Table 91. ABB Manufacturing Execution Systems for Pharma and Biotech Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. ABB Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 93. ABB Recent Development Table 94. Accevo Systems Company Information Table 95. Accevo Systems Business Overview Table 96. Accevo Systems Manufacturing Execution Systems for Pharma and Biotech Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Accevo Systems Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 98. Accevo Systems Recent Development Table 99. AmpleLogic Company Information Table 100. AmpleLogic Business Overview Table 101. AmpleLogic Manufacturing Execution Systems for Pharma and Biotech Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. AmpleLogic Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 103. AmpleLogic Recent Development Table 104. Siemens Software Company Information Table 105. Siemens Software Business Overview Table 106. Siemens Software Manufacturing Execution Systems for Pharma and Biotech Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Siemens Software Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 108. Siemens Software Recent Development Table 109. NNIT Company Information Table 110. NNIT Business Overview Table 111. NNIT Manufacturing Execution Systems for Pharma and Biotech Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. NNIT Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 113. NNIT Recent Development Table 114. Metronik Company Information Table 115. Metronik Business Overview Table 116. Metronik Manufacturing Execution Systems for Pharma and Biotech Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Metronik Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 118. Metronik Recent Development Table 119. Tulip Company Information Table 120. Tulip Business Overview Table 121. Tulip Manufacturing Execution Systems for Pharma and Biotech Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Tulip Manufacturing Execution Systems for Pharma and Biotech Product Portfolio Table 123. Tulip Recent Development Table 124. North America Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021-2026) & (US$ Million) Table 125. North America Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2027-2032) & (US$ Million) Table 126. North America Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021-2026) & (US$ Million) Table 127. North America Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2027-2032) & (US$ Million) Table 128. North America Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 129. North America Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (2021-2026) & (US$ Million) Table 130. North America Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (US$ Million) & (2027-2032) Table 131. Europe Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021-2026) & (US$ Million) Table 132. Europe Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2027-2032) & (US$ Million) Table 133. Europe Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021-2026) & (US$ Million) Table 134. Europe Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2027-2032) & (US$ Million) Table 135. Europe Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 136. Europe Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (2021-2026) & (US$ Million) Table 137. Europe Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (US$ Million) & (2027-2032) Table 138. China Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021-2026) & (US$ Million) Table 139. China Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2027-2032) & (US$ Million) Table 140. China Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021-2026) & (US$ Million) Table 141. China Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2027-2032) & (US$ Million) Table 142. Asia Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021-2026) & (US$ Million) Table 143. Asia Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2027-2032) & (US$ Million) Table 144. Asia Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021-2026) & (US$ Million) Table 145. Asia Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2027-2032) & (US$ Million) Table 146. Asia Manufacturing Execution Systems for Pharma and Biotech Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 147. Asia Manufacturing Execution Systems for Pharma and Biotech Revenue by Region (US$ Million) & (2021-2026) Table 148. Asia Manufacturing Execution Systems for Pharma and Biotech Revenue by Region (US$ Million) & (2027-2032) Table 149. SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021-2026) & (US$ Million) Table 150. SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2027-2032) & (US$ Million) Table 151. SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021-2026) & (US$ Million) Table 152. SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2027-2032) & (US$ Million) Table 153. SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 154. SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (2021-2026) & (US$ Million) Table 155. SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (US$ Million) & (2027-2032) Table 156. Research Programs/Design for This Report Table 157. Authors List of This Report Table 158. Secondary Sources Table 159. Primary Sources List of Figures Figure 1. Manufacturing Execution Systems for Pharma and Biotech Image Figure 2. Global Manufacturing Execution Systems for Pharma and Biotech Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Manufacturing Execution Systems for Pharma and Biotech Market Size Share 2021 VS 2025 VS 2032 Figure 4. Cloud-based Image Figure 5. On-premises Image Figure 6. Global Manufacturing Execution Systems for Pharma and Biotech Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Manufacturing Execution Systems for Pharma and Biotech Market Size Share 2021 VS 2025 VS 2032 Figure 8. Large Enterprises Image Figure 9. SMEs Image Figure 10. Global Manufacturing Execution Systems for Pharma and Biotech Market Size (US$ Million) & (2021-2032) Figure 11. Global Manufacturing Execution Systems for Pharma and Biotech Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Manufacturing Execution Systems for Pharma and Biotech Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Manufacturing Execution Systems for Pharma and Biotech Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Manufacturing Execution Systems for Pharma and Biotech Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Manufacturing Execution Systems for Pharma and Biotech Revenue Market Share by Type (2021-2032) Figure 18. Global Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Manufacturing Execution Systems for Pharma and Biotech Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Manufacturing Execution Systems for Pharma and Biotech Revenue Market Share by Application (2021-2032) Figure 21. North America Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Type (2021-2032) Figure 23. North America Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Application (2021-2032) Figure 24. North America Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Country (2021-2032) Figure 25. United States Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Type (2021-2032) Figure 30. Europe Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Application (2021-2032) Figure 31. Europe Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Country (2021-2032) Figure 32. Germany Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Type (2021-2032) Figure 42. China Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Application (2021-2032) Figure 43. Asia Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Type (2021-2032) Figure 45. Asia Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Application (2021-2032) Figure 46. Asia Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Region (2021-2032) Figure 47. Japan Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Type (2021-2032) Figure 55. SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Application (2021-2032) Figure 56. SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Country (2021-2032) Figure 57. Brazil Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Manufacturing Execution Systems for Pharma and Biotech Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Cloud-based
  • On-premises
Applications
  • Large Enterprises
  • SMEs
Companies covered
  • Lonza
  • Vimachem
  • Korber
  • MasterControl
  • POMS Corporation
  • AspenTech
  • GE Vernova
  • 凯睿德
  • Dassault Systemes
  • IBM
  • Rockwell Automation
  • ABB
  • Accevo Systems
  • AmpleLogic
  • Siemens Software
  • NNIT
  • Metronik
  • Tulip

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Manufacturing Execution Systems for Pharma and Biotech Market by Type
  3. 1.2.1 Global Manufacturing Execution Systems for Pharma and Biotech Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Cloud-based
  5. 1.2.3 On-premises
  6. 1.3 Manufacturing Execution Systems for Pharma and Biotech Market by Application
  7. 1.3.1 Global Manufacturing Execution Systems for Pharma and Biotech Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Large Enterprises
  9. 1.3.3 SMEs
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Manufacturing Execution Systems for Pharma and Biotech Market Dynamics
  1. 2.1 Manufacturing Execution Systems for Pharma and Biotech Industry Trends
  2. 2.2 Manufacturing Execution Systems for Pharma and Biotech Industry Drivers
  3. 2.3 Manufacturing Execution Systems for Pharma and Biotech Industry Opportunities and Challenges
  4. 2.4 Manufacturing Execution Systems for Pharma and Biotech Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Manufacturing Execution Systems for Pharma and Biotech Market Perspective (2021-2032)
  2. 3.2 Global Manufacturing Execution Systems for Pharma and Biotech Growth Trends by Region
  3. 3.2.1 Global Manufacturing Execution Systems for Pharma and Biotech Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Manufacturing Execution Systems for Pharma and Biotech Market Size by Region (2021-2026)
  5. 3.2.3 Global Manufacturing Execution Systems for Pharma and Biotech Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Manufacturing Execution Systems for Pharma and Biotech Revenue by Players
  2. 4.1.1 Global Manufacturing Execution Systems for Pharma and Biotech Revenue by Players (2021-2026)
  3. 4.1.2 Global Manufacturing Execution Systems for Pharma and Biotech Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Manufacturing Execution Systems for Pharma and Biotech Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Manufacturing Execution Systems for Pharma and Biotech Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Manufacturing Execution Systems for Pharma and Biotech Key Players Headquarters & Area Served
  7. 4.4 Global Manufacturing Execution Systems for Pharma and Biotech Players, Product Type & Application
  8. 4.5 Global Manufacturing Execution Systems for Pharma and Biotech Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Manufacturing Execution Systems for Pharma and Biotech Market CR5 and HHI
  11. 4.6.3 2025 Manufacturing Execution Systems for Pharma and Biotech Tier 1, Tier 2, and Tier 3
5 Manufacturing Execution Systems for Pharma and Biotech Market Size by Type
  1. 5.1 Global Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021-2032)
  3. 5.3 Global Manufacturing Execution Systems for Pharma and Biotech Revenue Market Share by Type (2021-2032)
6 Manufacturing Execution Systems for Pharma and Biotech Market Size by Application
  1. 6.1 Global Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021-2032)
  3. 6.3 Global Manufacturing Execution Systems for Pharma and Biotech Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Lonza
  2. 7.1.1 Lonza Company Information
  3. 7.1.2 Lonza Business Overview
  4. 7.1.3 Lonza Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Lonza Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  6. 7.1.5 Lonza Recent Developments
  7. 7.2 Vimachem
  8. 7.2.1 Vimachem Company Information
  9. 7.2.2 Vimachem Business Overview
  10. 7.2.3 Vimachem Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Vimachem Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  12. 7.2.5 Vimachem Recent Developments
  13. 7.3 Korber
  14. 7.3.1 Korber Company Information
  15. 7.3.2 Korber Business Overview
  16. 7.3.3 Korber Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Korber Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  18. 7.3.5 Korber Recent Developments
  19. 7.4 MasterControl
  20. 7.4.1 MasterControl Company Information
  21. 7.4.2 MasterControl Business Overview
  22. 7.4.3 MasterControl Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  23. 7.4.4 MasterControl Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  24. 7.4.5 MasterControl Recent Developments
  25. 7.5 POMS Corporation
  26. 7.5.1 POMS Corporation Company Information
  27. 7.5.2 POMS Corporation Business Overview
  28. 7.5.3 POMS Corporation Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  29. 7.5.4 POMS Corporation Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  30. 7.5.5 POMS Corporation Recent Developments
  31. 7.6 AspenTech
  32. 7.6.1 AspenTech Company Information
  33. 7.6.2 AspenTech Business Overview
  34. 7.6.3 AspenTech Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  35. 7.6.4 AspenTech Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  36. 7.6.5 AspenTech Recent Developments
  37. 7.7 GE Vernova
  38. 7.7.1 GE Vernova Company Information
  39. 7.7.2 GE Vernova Business Overview
  40. 7.7.3 GE Vernova Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  41. 7.7.4 GE Vernova Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  42. 7.7.5 GE Vernova Recent Developments
  43. 7.8 凯睿德
  44. 7.8.1 凯睿德 Company Information
  45. 7.8.2 凯睿德 Business Overview
  46. 7.8.3 凯睿德 Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  47. 7.8.4 凯睿德 Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  48. 7.8.5 凯睿德 Recent Developments
  49. 7.9 Dassault Systemes
  50. 7.9.1 Dassault Systemes Company Information
  51. 7.9.2 Dassault Systemes Business Overview
  52. 7.9.3 Dassault Systemes Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Dassault Systemes Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  54. 7.9.5 Dassault Systemes Recent Developments
  55. 7.10 IBM
  56. 7.10.1 IBM Company Information
  57. 7.10.2 IBM Business Overview
  58. 7.10.3 IBM Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  59. 7.10.4 IBM Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  60. 7.10.5 IBM Recent Developments
  61. 7.11 Rockwell Automation
  62. 7.11.1 Rockwell Automation Company Information
  63. 7.11.2 Rockwell Automation Business Overview
  64. 7.11.3 Rockwell Automation Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Rockwell Automation Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  66. 7.11.5 Rockwell Automation Recent Developments
  67. 7.12 ABB
  68. 7.12.1 ABB Company Information
  69. 7.12.2 ABB Business Overview
  70. 7.12.3 ABB Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  71. 7.12.4 ABB Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  72. 7.12.5 ABB Recent Developments
  73. 7.13 Accevo Systems
  74. 7.13.1 Accevo Systems Company Information
  75. 7.13.2 Accevo Systems Business Overview
  76. 7.13.3 Accevo Systems Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Accevo Systems Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  78. 7.13.5 Accevo Systems Recent Developments
  79. 7.14 AmpleLogic
  80. 7.14.1 AmpleLogic Company Information
  81. 7.14.2 AmpleLogic Business Overview
  82. 7.14.3 AmpleLogic Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  83. 7.14.4 AmpleLogic Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  84. 7.14.5 AmpleLogic Recent Developments
  85. 7.15 Siemens Software
  86. 7.15.1 Siemens Software Company Information
  87. 7.15.2 Siemens Software Business Overview
  88. 7.15.3 Siemens Software Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Siemens Software Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  90. 7.15.5 Siemens Software Recent Developments
  91. 7.16 NNIT
  92. 7.16.1 NNIT Company Information
  93. 7.16.2 NNIT Business Overview
  94. 7.16.3 NNIT Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  95. 7.16.4 NNIT Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  96. 7.16.5 NNIT Recent Developments
  97. 7.17 Metronik
  98. 7.17.1 Metronik Company Information
  99. 7.17.2 Metronik Business Overview
  100. 7.17.3 Metronik Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Metronik Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  102. 7.17.5 Metronik Recent Developments
  103. 7.18 Tulip
  104. 7.18.1 Tulip Company Information
  105. 7.18.2 Tulip Business Overview
  106. 7.18.3 Tulip Manufacturing Execution Systems for Pharma and Biotech Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Tulip Manufacturing Execution Systems for Pharma and Biotech Product Portfolio
  108. 7.18.5 Tulip Recent Developments
8 North America
  1. 8.1 North America Manufacturing Execution Systems for Pharma and Biotech Revenue (2021-2032)
  2. 8.2 North America Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021-2032)
  3. 8.2.1 North America Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021-2026)
  4. 8.2.2 North America Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2027-2032)
  5. 8.3 North America Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Type (2021-2032)
  6. 8.4 North America Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021-2032)
  7. 8.4.1 North America Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021-2026)
  8. 8.4.2 North America Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2027-2032)
  9. 8.5 North America Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Application (2021-2032)
  10. 8.6 North America Manufacturing Execution Systems for Pharma and Biotech Revenue by Country
  11. 8.6.1 North America Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (2021-2026)
  13. 8.6.3 North America Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Manufacturing Execution Systems for Pharma and Biotech Revenue (2021-2032)
  2. 9.2 Europe Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021-2032)
  3. 9.2.1 Europe Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021-2026)
  4. 9.2.2 Europe Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2027-2032)
  5. 9.3 Europe Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Type (2021-2032)
  6. 9.4 Europe Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021-2032)
  7. 9.4.1 Europe Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021-2026)
  8. 9.4.2 Europe Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2027-2032)
  9. 9.5 Europe Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Application (2021-2032)
  10. 9.6 Europe Manufacturing Execution Systems for Pharma and Biotech Revenue by Country
  11. 9.6.1 Europe Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (2021-2026)
  13. 9.6.3 Europe Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Manufacturing Execution Systems for Pharma and Biotech Revenue (2021-2032)
  2. 10.2 China Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021-2032)
  3. 10.2.1 China Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021-2026)
  4. 10.2.2 China Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2027-2032)
  5. 10.3 China Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Type (2021-2032)
  6. 10.4 China Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021-2032)
  7. 10.4.1 China Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021-2026)
  8. 10.4.2 China Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2027-2032)
  9. 10.5 China Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Manufacturing Execution Systems for Pharma and Biotech Revenue (2021-2032)
  2. 11.2 Asia Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021-2032)
  3. 11.2.1 Asia Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021-2026)
  4. 11.2.2 Asia Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2027-2032)
  5. 11.3 Asia Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Type (2021-2032)
  6. 11.4 Asia Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021-2032)
  7. 11.4.1 Asia Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021-2026)
  8. 11.4.2 Asia Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2027-2032)
  9. 11.5 Asia Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Application (2021-2032)
  10. 11.6 Asia Manufacturing Execution Systems for Pharma and Biotech Revenue by Country
  11. 11.6.1 Asia Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (2021-2026)
  13. 11.6.3 Asia Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue (2021-2032)
  2. 12.2 SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue by Type (2027-2032)
  5. 12.3 SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue by Application (2027-2032)
  9. 12.5 SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue by Country
  11. 12.6.1 SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Manufacturing Execution Systems for Pharma and Biotech Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst